| DC7804 |
Anacetrapib(MK0859)
Featured
|
Anacetrapib (MK0859) is a potent, selective, reversible rhCETP and mutant CETP(C13S) inhibitor with IC50 of 7.9 nM and 11.8 nM, increases HDL-C and decreases LDL-C, does not increase aldosterone or blood pressure. Phase 3. |
|
| DC11098 |
CKD-519 |
CKD-519 (Rocacetrapib, CKD519) is a potent, selective cholesteryl ester transfer protein (CETP) inhibitor, inhibits the CETP-mediated transfer of cholesteryl ester in human serum with IC50 of 2.3 nM. |
|
| DC7125 |
Evacetrapib (LY2484595)
Featured
|
Evacetrapib (LY2484595) is a potent and selective inhibitor of CETP with IC50 of 5.5 nM, elevates HDL cholesterol without increases in aldosterone or blood pressure. |
|
| DC10134 |
Obicetrapib (AMG-899,TA-8995)
Featured
|
Obicetrapib is a CETP inhibitor, on the elevation of high-density lipoprotein cholesterol (HDL-C) and reduction of low-density lipoprotein cholesterol (LDL-C), alone and in combination with statin therapy. |
|
| DC7519 |
Torcetrapib
Featured
|
Torcetrapib is a CETP inhibitor with IC50 of 37 nM, elevates HDL-C and reduces nonHDL-C in plasma. Phase 3. |
|
| DC28440 |
CP-532623
Featured
|
CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties. |
|
| DC46394 |
MK-8262
Featured
|
MK-8262 is an orally active and potent cholesteryl ester transfer protein (CETP) inhibitor with an IC50 of 53 nM and a log D of 5.3. MK-8262, a bistrifluoromethyl analogue, has the potential for coronary heart disease (CHD) correlated high-density lipoprotein (HDL) and low-density lipoprotein (LDL) research. |
|
| DC48351 |
CETP-IN-4 |
CETP-IN-4 is a cholesteryl ester transfer protein (CETP) inhibitor. |
|
